Edwards Lifesciences holders approve 7 million more shares for stock incentive plan
At its May 7, 2026 annual meeting, Edwards Lifesciences stockholders approved an amendment to the Long-Term Stock Incentive Compensation Program that adds 7,000,000 shares, bringing the total share limit to 341,500,000. Stockholders also elected all nine director nominees and approved the advisory vote on named executive officer compensation and the auditor ratification.
Key points
- Share limit under the Long-Term Stock Program rises by 7,000,000 shares to 341,500,000 shares.
- Stockholder approval of the amended program: 456,675,201 for and 19,210,539 against.
- All nine director nominees were elected, including David T. Feinberg, MD, and Bernard J. Zovighian.
- Advisory executive pay proposal passed with 424,961,639 for and 50,924,101 against.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.